ACADIA Pharmaceuticals Inc. (ACAD) Financials

ACAD Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 1.6 billion 357.2 million
Dec. 31, 2025 1.6 billion 336.8 million
Sept. 30, 2025 1.3 billion 413.5 million
June 30, 2025 1.2 billion 403.2 million

ACAD Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 28.8 million ?
Dec. 31, 2025 -52.7 million 13.2 million
Sept. 30, 2025 73.9 million 13.2 million
June 30, 2025 162.5 million 14.3 million

ACAD Net Income

No data available :(

ACAD Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 851.5 million - 39.0 million
Dec. 31, 2025 819.7 million - 40.6 million
Sept. 30, 2025 847.0 million - 43.0 million
June 30, 2025 762.0 million - 44.6 million

ACAD Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 172.7 million
Dec. 31, 2025 171.4 million
Sept. 30, 2025 170.7 million
June 30, 2025 168.7 million

ACAD Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 5.2 million 76.9 million 171.0 million -
Dec. 31, 2025 4.0 million 84.8 million 155.6 million -
Sept. 30, 2025 388000 87.8 million 133.4 million -
June 30, 2025 98.5 million 78.0 million 133.5 million -

ACAD Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 268.1 million 24.8 million
Dec. 31, 2025 284.0 million 26.2 million
Sept. 30, 2025 278.6 million 21.6 million
June 30, 2025 264.6 million 20.7 million

ACAD

Price: $21.26

52 week price:
19.69
28.35

Earnings Per Share: 2.21 USD

P/E Ratio: 9.86

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 1.4 million

Ebitda: -65.6 million

Market Capitalization: 3.7 billion

Links: